<DOC>
	<DOCNO>NCT00814723</DOCNO>
	<brief_summary>Patients coronary heart disease ( CHD ) CHD equivalent ( e. g. diabetes mellitus ) often abnormalities lipid ( hypercholesterolemia ) . Besides , hypercholesterolemia evident risk factor atherosclerosis . Hitherto , study patient primary hypercholesterolemia combination therapy statin ( HMG-Co-reductase inhibitor ) ezetimib investigate . This combination therapy effective reduce low density lipoprotein cholesterol ( LDL-C ) total cholesterol level compare monotherapy .</brief_summary>
	<brief_title>Fluvastatin 80 mg Ret . v Combination With Ezetimibe 10 mg Patients With High Cardiovascular Risk</brief_title>
	<detailed_description>Ezetimibe , cholesterol-absorption inhibitor , significantly lower low-density lipoprotein cholesterol ( LDL-C ) administer addition statin treatment . The effect ezetimibe incidence progression vascular disease elusive . Therefore , objective examine effect fluvastatin fluvastatin plus ezetimibe lipoprotein subfractions patient diabetes mellitus and/or coronary heart disease .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>Patients CHD CHD equivalent LDL 100160 mg/dl Male female sex Normal value CK , AST ALT Normal kidney function CHD Stage IIIIV St. p. myocardial infarction coronary artery bypass graft Pregnancy breastfeed Premenopausal woman without certain contraception Known hypersensitivity HMGCoA reductase inhibitor ezetimib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>